On September 23, 2019 Nektar Therapeutics (Nasdaq: NKTR) reported that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper), which is being held from September 25 to September 28, 2019, at the Espace Grand Arche de la Defense in Paris, France (Press release, Nektar Therapeutics, SEP 23, 2019, View Source [SID1234539720]). The PIVOT-02 study is evaluating bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in a range of advanced and/or metastatic solid tumor settings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation:

Abstract #A001: "Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study", Tolaney, S., et al.

Session Date and Time: Thursday, September 26th from 1:00 p.m. – 3:00 p.m. and 6:30 p.m. – 8:00 p.m. Central European Time

Company to Host Webcast Conference Call at CRI-CIMT-EATI-AACR:
The company will host a webcast conference call with Dr. Sara M. Tolaney, MPH, Associate Director of the Susan F. Smith Center for Women’s Cancers and Assistant Professor of Medicine at Harvard Medical School and company management on Thursday, September 26th at 8:30 a.m. Eastern time during the CRI-CIMT-EATI-AACR conference following presentation of data. The webcast conference call will be accessible from the Investor Events page of Nektar’s website at View Source